First Tracks Biotherapeutics Inc
TRAX · NASDAQ · USD · Market cap $1.7B · 104 employees
First Tracks Biotherapeutics, Inc.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 12:17 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price41.64 USD at the 20 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 20 Nov 2026
- Our regime readAccumulation, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.00)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $57.00 to $83.28, base estimate $70.00 (screen dated 2026-11-20).
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.00, read 2026-11-20
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
First Tracks Biotherapeutics Inc holds its Accumulation at $41.64. The statistical read favours the sellers, held for 69 days.
| Phase | Accumulation |
| Quantitative state | The statistical read favours the sellers, held for 69 days |
| Price at the screen | $41.64 |
| Valuation | N/A trailing · -12.03 forward price to earnings |
| Values screen | FAIL · score 70.0 |
Five Screens: TRAX's Results
FAIL. Interest-bearing securities
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 3.63% | Below 33% | Pass |
| Interest-bearing cash | 59.36% | Below 33% | Fail |
| Receivables | 27.85% | Below 49% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
First Tracks Biotherapeutics's business is fine, but its cash and interest-bearing securities are about 59% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when TRAX's ethical verdict changes
Today TRAX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 41% discount to our $70.00 fair value.
USD, 2026-11-20 screen. A 40.5% under base.
Street: 12 covering, consensus Strong Buy. Average target +68%.
Early Biotech Still Waiting On First Proof
Picture a lab bench with one promising molecule and no sales yet. First Tracks is exactly that, a clinical stage player whose lead candidate targets autoimmune inflammation but has delivered zero revenue and zero profit margin so far. The negative forward earnings multiple simply reflects cash burn that every similar name carries until trials clear later stages.
We pass because the opportunity rating shows none. An unknown moat, no current earnings, and heavy dependence on a single unproven asset outweigh the 15 percent gap to our fair value and the analysts' strong buy chorus. Ethical clearance is welcome, yet it does not turn an incomplete story into an investable one.
The real risk sits in trial failure or dilution that resets the clock, a pattern common in this sector. Peak earnings are nowhere in sight, so the low multiple offers no bargain, only a reminder that hope is not a margin. Analysis, not advice.
| Forward P/E | -12.0x |
| EPS, trailing | -4.71 |
| EPS, forward | -3.46 |
| Profit margin | 0.0%currently unprofitable |
| Debt to equity | 2.50heavy leverage: higher risk if revenue softens |
| Current ratio | 9.16comfortably covers its short-term bills |
| 52-week range | 14.72 - 54.78 |
| Market cap | $1.7B |
| Employees | 104 |
TRAX-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from markup to accumulation since the last review.
Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences Yahoo Finance · 18d ago
- First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Yahoo Finance · 18d ago
- First Tracks Biotherapeutics Announces $200 Million Private Placement Yahoo Finance · 15 Oct 2026
- 7 Reasons First Tracks Biotherapeutics (TRAX) Looks Pricey Following ANB033 Trial Data Yahoo Finance · 13 Oct 2026
- First Tracks Biotherapeutics (TRAX) Stock Looks Rich Following Phase 1b Celiac Data Yahoo Finance · 13 Oct 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $18.76 | -12.5% | · | $875 | -12.5% |
| 2 months | $23.50 | -30.1% | · | $699 | -30.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever TRAX does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.